P53 and its molecular basis to chemoresistance in breast cancer.
about
Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticlesHypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell typesp53 is a key regulator for osthole-triggered cancer pathogenesis.APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsExpression of PD-L1 and prognosis in breast cancer: a meta-analysis.Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy.RORα, a potential tumor suppressor and therapeutic target of breast cancer.Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancerSensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cellsMDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53.Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients.Profiling the Behavior of Distinct Populations of Head and Neck Cancer Stem Cells.Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.Elevated expression of thyroid hormone receptor-interacting protein 13 drives tumorigenesis and affects clinical outcome.A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.
P2860
Q27026080-415C52B7-7814-4A4A-B9AA-30D074941EB9Q28484877-FAD86D4E-B699-46CF-A69E-B457695677D6Q33821688-F355F0DD-1F04-40FF-81FF-4F91AB982D00Q35667409-AE48C213-5C8E-477D-865B-A1E62D479DABQ36353438-6E461CD0-541A-4A93-A6FF-9A0B27A62404Q36466316-F77664D9-76DB-48BE-B10E-42A482819A42Q36538295-865DF8EA-9366-456D-8022-4ED68AD81E04Q36904012-4AA63207-1DCE-4180-8CF1-F09ECC123444Q37520579-D3669B70-2183-429D-BB20-EAA84E9A62B1Q37688946-C682D10B-E189-4A92-9148-8588CF365A16Q37703117-F11FE3A5-4AEE-47FB-9668-A8D908DE975FQ39020051-6F94709D-B5CA-4675-93D6-76B3C4EAC272Q39070928-B44F6289-D47E-476D-B2DC-EFDE539099D1Q41518218-6B96ADFE-361A-4583-8BED-6F24BEDC0513Q42089892-F0C07D1E-8525-478C-B70A-8E8AFD8339CDQ42367187-7731A808-D510-4AD0-B45A-699FE532374DQ50551376-78F968E6-DE10-4F21-BADA-C37D80EFC031Q50875340-01AB2DF9-042B-491F-92B2-D9AF9AD4BA8EQ51759206-EEF6E298-D16A-46D3-AA91-130B35DD217F
P2860
P53 and its molecular basis to chemoresistance in breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
P53 and its molecular basis to chemoresistance in breast cancer.
@en
P53 and its molecular basis to chemoresistance in breast cancer.
@nl
type
label
P53 and its molecular basis to chemoresistance in breast cancer.
@en
P53 and its molecular basis to chemoresistance in breast cancer.
@nl
prefLabel
P53 and its molecular basis to chemoresistance in breast cancer.
@en
P53 and its molecular basis to chemoresistance in breast cancer.
@nl
P2860
P1476
P53 and its molecular basis to chemoresistance in breast cancer.
@en
P2860
P304
P356
10.1517/14728222.2011.640322
P407
P478
16 Suppl 1
P577
2012-02-08T00:00:00Z